A Randomized, Controlled Trial of Costs Associated With Anemia Therapy in Hemodialysis Patients Treated With Intravenous Darbepoetin Alfa Versus Epoetin Alfa

NCT02817555 Phase 4 COMPLETED Results posted

The purpose of this study is to determine if there is a cost difference between darbepoetin alfa and epoetin alfa when used intravenously to treat anemia in hemodialysis patients.

Details

Lead sponsor	Andrea L Woodland
Phase	Phase 4
Status	COMPLETED
Enrolment	50
Start date	2010-09
Completion	2013-05

Conditions

• Anemia
• Chronic Kidney Disease

Interventions

• Epoetin Alfa
• Darbepoetin alfa

Primary outcomes

• Cost of Erythropoiesis Stimulating Agent — 12 months
  total cost over 12 months in Canadian dollars